These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
440 related articles for article (PubMed ID: 31926199)
21. Cannabinoid Receptor 1 Inhibition in Chronic Kidney Disease: A New Therapeutic Toolbox. Dao M; François H Front Endocrinol (Lausanne); 2021; 12():720734. PubMed ID: 34305821 [TBL] [Abstract][Full Text] [Related]
22. Hepatic targeting of the centrally active cannabinoid 1 receptor (CB Hirsch S; Hinden L; Naim MB; Baraghithy S; Permyakova A; Azar S; Nasser T; Portnoy E; Agbaria M; Nemirovski A; Golomb G; Tam J J Control Release; 2023 Jan; 353():254-269. PubMed ID: 36442615 [TBL] [Abstract][Full Text] [Related]
23. Reports of the death of CB1 antagonists have been greatly exaggerated: recent preclinical findings predict improved safety in the treatment of obesity. McLaughlin PJ Behav Pharmacol; 2012 Sep; 23(5-6):537-50. PubMed ID: 22743603 [TBL] [Abstract][Full Text] [Related]
24. Beneficial metabolic effects of CB1R anti-sense oligonucleotide treatment in diet-induced obese AKR/J mice. Tang Y; Ho G; Li Y; Hall MA; Hills RL; Black SC; Liang Y; Demarest KT PLoS One; 2012; 7(8):e42134. PubMed ID: 22870290 [TBL] [Abstract][Full Text] [Related]
30. Role of Cannabinoid Receptor Type 1 in Insulin Resistance and Its Biological Implications. Nagappan A; Shin J; Jung MH Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31035653 [TBL] [Abstract][Full Text] [Related]
31. A patent update on cannabinoid receptor 1 antagonists (2015-2018). Amato G; Khan NS; Maitra R Expert Opin Ther Pat; 2019 Apr; 29(4):261-269. PubMed ID: 30889997 [TBL] [Abstract][Full Text] [Related]
32. Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk. Janero DR; Lindsley L; Vemuri VK; Makriyannis A Expert Opin Drug Discov; 2011 Oct; 6(10):995-1025. PubMed ID: 22646861 [TBL] [Abstract][Full Text] [Related]
33. Modulation of Renal GLUT2 by the Cannabinoid-1 Receptor: Implications for the Treatment of Diabetic Nephropathy. Hinden L; Udi S; Drori A; Gammal A; Nemirovski A; Hadar R; Baraghithy S; Permyakova A; Geron M; Cohen M; Tsytkin-Kirschenzweig S; Riahi Y; Leibowitz G; Nahmias Y; Priel A; Tam J J Am Soc Nephrol; 2018 Feb; 29(2):434-448. PubMed ID: 29030466 [TBL] [Abstract][Full Text] [Related]
34. Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle. Eckardt K; Sell H; Taube A; Koenen M; Platzbecker B; Cramer A; Horrighs A; Lehtonen M; Tennagels N; Eckel J Diabetologia; 2009 Apr; 52(4):664-74. PubMed ID: 19089403 [TBL] [Abstract][Full Text] [Related]
35. Energy balance regulation by endocannabinoids at central and peripheral levels. Quarta C; Mazza R; Obici S; Pasquali R; Pagotto U Trends Mol Med; 2011 Sep; 17(9):518-26. PubMed ID: 21816675 [TBL] [Abstract][Full Text] [Related]
36. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats. Pavón FJ; Serrano A; Pérez-Valero V; Jagerovic N; Hernández-Folgado L; Bermúdez-Silva FJ; Macías M; Goya P; de Fonseca FR J Neuroendocrinol; 2008 May; 20 Suppl 1():116-23. PubMed ID: 18426510 [TBL] [Abstract][Full Text] [Related]
37. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders. Silvestri C; Di Marzo V Expert Opin Investig Drugs; 2012 Sep; 21(9):1309-22. PubMed ID: 22780328 [TBL] [Abstract][Full Text] [Related]
38. Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice. Tai S; Vasiljevik T; Sherwood AM; Eddington S; Wilson CD; Prisinzano TE; Fantegrossi WE Drug Alcohol Depend; 2018 Nov; 192():285-293. PubMed ID: 30300803 [TBL] [Abstract][Full Text] [Related]
39. Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders. Beardsley PM; Thomas BF Behav Pharmacol; 2005 Sep; 16(5-6):275-96. PubMed ID: 16148435 [TBL] [Abstract][Full Text] [Related]
40. Neutral CB1 Receptor Antagonists as Pharmacotherapies for Substance Use Disorders: Rationale, Evidence, and Challenge. Soler-Cedeno O; Xi ZX Cells; 2022 Oct; 11(20):. PubMed ID: 36291128 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]